Aurobindo Pharma Ltd.
NSE: AUROPHARMAAurobindo Pharma Ltd.: A 30-second snapshot
Aurobindo Pharma (AUROPHARMA) trades at ₹1,497.50, up 29.85% over the past year and within 1.05% of its 52-week high. The stock carries a trailing PE of 25.16 and forward PE of 19.77, with a profit margin of 10.51% and 5-year revenue growth of 8.4%. A debt-to-equity ratio of 22.25 alongside a rising debt trend and limited free cash flow generation represent the most prominent data-level concerns.
P/E
25.2
Forward P/E
19.8
ROE
—
Debt / Equity
22.25
Profit Margin
+10.5%
Div. Yield
+0.3%
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
51/100
News
5 headlines · 1 positive · 0 negative
ITC, Auro Pharma, Power Grid: Stocks to buy— target prices, stop loss, risk-reward & more - Business Today
Business Today
MSN Money - MSN
MSN
Top stocks in news: HCL Tech, Suzlon, SBI, Auro Pharma, HDFC Life, BEML, Tata Elxsi, HZL - Business Today
Business Today
Top stocks in news: Wipro, HDFC Life, Jio Financial, Auro Pharma, RVNL, AngelOne, Om Power - Business Today
Business Today
Business News | ICICI Lombard, GMR Airports, and Aurobindo Pharma Among Shares To Remain in Spotlight on April 16 - LatestLY
LatestLY
Recent context
- ·Aurobindo Pharma appeared across multiple Business Today market round-ups in April–May 2026, cited alongside diverse blue-chip names in intraday stock-watch contexts; no company-specific earnings or regulatory events dominated the 5-article news sample.
- ·News sentiment across 5 articles was 1 positive and 4 neutral with 0 negative; the thin sample size limits confidence in the aggregate sentiment read.
- ·The stock sits near a 52-week high (drawdown -1.05%) with identified support levels at ₹1,367, ₹1,240, and ₹1,170.20 — the nearest support is approximately 8.7% below the current price.
Strengths
- +Lowest PE in the 6-stock pharma peer set at 25.16 — peers range from 25.89 (Dr. Reddys) to 72.04 (Max Healthcare), placing AUROPHARMA at the most modest earnings multiple in the group.
- +Price up 29.85% over 12 months and 24.41% over 3 months; stock trades above both the 50-DMA (₹1,344.8) and 200-DMA (₹1,191.19), with a 52-week drawdown of only -1.05%.
- +Forward PE of 19.77 represents an 11.5-point compression versus trailing PE of 25.16, implying analysts model meaningful earnings expansion over the next 12 months.
- +Mean analyst rating of 1.85 across 27 analysts (1–5 scale, lower = more constructive); coverage count of 27 indicates broad institutional research attention.
Weaknesses
- −Debt-to-equity of 22.25 is substantially elevated versus pharma peers; combined with a rising debt trend and FCF positive in only 2 of tracked years, leverage profile warrants close attention.
- −Persistence score of 27/100 and zero years with ROE above 15% in tracked history indicate weak earnings quality consistency over the measurement period.
- −Quality score of 44/100 places AUROPHARMA 3rd of 6 in the sector peer set — below Max Healthcare (54) and Sun Pharma (50), mid-pack among peers.
- −RSI at 72.51 is in overbought territory following a 24.41% 3-month rally; no resistance levels are identified in the technical data, leaving upper reference points undefined.
Open questions
- ?Does the debt-to-equity of 22.25 reflect a structural feature of Aurobindos capital model (e.g. working capital intensity in generics manufacturing), or has leverage risen due to a specific acquisition or capacity expansion cycle?
- ?The forward PE implies significant earnings growth relative to trailing — what are the key product pipelines or regulatory approvals that analysts may be modelling, and how dependent is the earnings expansion on US FDA clearances?
- ?Given zero years of ROE above 15% in the persistence data, does the current price momentum reflect a genuine shift in return-on-capital trajectory, or is it primarily driven by multiple re-rating within the pharma sector?
- ?With the nearest technical support 8.7% below current price and RSI in overbought territory, how has AUROPHARMA historically behaved following extended momentum runs — and how does that compare to broader pharma index behavior?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| AUROPHARMA | Aurobindo Pharma Ltd.You're viewing | 25.2 | — | 44 |
| Industry avg | across 5 peers | 46.7 | +11.8% | 38 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.0 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.0 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.9 | — | 25 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 25.9 | +11.8% | 17 |
Technical state
Current price
₹1,497.50
SMA 50
₹1,344.80
SMA 200
₹1,191.19
RSI (14)
72.5 (overbought)
From 52w high
-1.1%
1Y return
+29.9%
3M return
+24.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- highDebt-to-equity of 22.25 is substantially elevated — for context, sector peer Dr. Reddys reports D/E well below 1; combined with a rising debt trend and FCF positive in only 2 of tracked years, leverage risk is material.
- mediumROE is unavailable for reported periods; persistence shows zero years with ROE above 15% in tracked history, and consistency score of 27/100 signals weak earnings quality relative to the sector.
- mediumRSI at 72.51 is in overbought territory; stock is up 24.41% over 3 months and sits within 1.05% of its 52-week high with no identified resistance levels, leaving upside reference points undefined.
- lowNews sample is sparse at 5 articles total (1 positive, 4 neutral, 0 negative); sentiment signal is thin and may not reflect the full information environment.
Cross-section contradictions
- Persistence shows zero years of ROE above 15%, FCF positive only 2 of tracked years, and consistency score of 27/100 — yet the stock is up 29.85% over 1 year and trades within 1.05% of its 52-week high; price momentum is not corroborated by underlying quality metrics.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 14 May 2026 · rotates through NIFTY 500 every ~5 days